Flippo Brittany, Stone Bradley, Stahr Shelbie, Khalil Mahmoud, Davis Rodney, Kamel Mohamed, Singh Manisha
University of Arkansas for Medical Sciences, Little Rock, AR, United States.
JMIR Form Res. 2022 Jan 10;6(1):e19750. doi: 10.2196/19750.
Obesity is significantly associated with renal cell carcinoma. Surgery is the preferred treatment for demarcated lesions of renal cell carcinoma; however, obesity increases the complexity of surgical outcomes. Minimally invasive surgical techniques are preferred over open partial nephrectomy (OPN), but controversy remains regarding the most efficacious technique in patients with obesity.
This study aims to determine whether minimally invasive partial nephrectomy (MIPN) or OPN better preserves renal function and investigate short- and long-term renal outcomes in patients with obesity undergoing a partial nephrectomy.
We conducted a retrospective chart review of 242 adult patients aged ≥18 years who underwent MIPN or OPN between January 1, 2005, and December 31, 2016, at the University of Arkansas for Medical Sciences. Using creatinine as a measure of kidney function, patients' preoperative levels were compared with their postoperative levels in 2-time frames: short (3-6 months postsurgery) or long (>6 months). The primary outcome was the change in creatinine values from preoperative to >6 months postoperatively in patients with obesity. Secondary outcomes included the change in creatinine values from preoperative to 3 to 6 months postoperatively in patients with obesity who underwent MIPN versus OPN. We also analyzed the creatinine values of nonobese patients (BMI <30) who underwent partial nephrectomy using the same time frames. Unconditional logistic regression was used to estimate crude and multivariable-adjusted odds ratios (ORs) and 95% CI to observe associations between surgery type and changes in creatinine values from while stratifying for obesity.
A total of 140 patients were included in the study, of whom 75 were obese and 65 were nonobese. At >6 months after MIPN (n=20), the odds of patients with obesity having a decrease or no change in creatinine values was 1.24 times higher than those who had OPN (n=13; OR 1.24, 95% CI 0.299-6.729; P=.80). At 3 to 6 months after MIPN (n=27), the odds were 0.62 times lower than those after OPN (n=17; OR 0.62, 95% CI 0.140-2.753; P=.56). In the nonobese group, at 3 to 6 months after undergoing minimally invasive surgery (n=18), the odds of having a decrease or no change in creatinine values was 4.86 times higher than those who had open surgery (n=21; OR 4.86, 95% CI 1.085-21.809; P=.04). At more than 6 months after MIPN (n=14), the odds were 4.13 times higher than those after OPN (n=11; OR 4.13, 95% CI 0.579-29.485; P=.16).
We observed a nonstatistically significant preservation of renal function in patients with obesity who underwent OPN at 3 to 6 months postoperatively. Conversely, after 6 months, the same was true for MIPN, indicating the long-term benefit of MIPN. In the nonobese group, MIPN was favored over OPN.
肥胖与肾细胞癌显著相关。手术是肾细胞癌局限性病变的首选治疗方法;然而,肥胖会增加手术结果的复杂性。与开放性部分肾切除术(OPN)相比,微创外科技术更受青睐,但对于肥胖患者最有效的技术仍存在争议。
本研究旨在确定微创部分肾切除术(MIPN)或OPN是否能更好地保留肾功能,并调查接受部分肾切除术的肥胖患者的短期和长期肾脏结局。
我们对2005年1月1日至2016年12月31日期间在阿肯色大学医学科学分校接受MIPN或OPN的242名年龄≥18岁的成年患者进行了回顾性病历审查。以肌酐作为肾功能指标,在两个时间段将患者术前水平与术后水平进行比较:短期(术后3 - 6个月)或长期(>6个月)。主要结局是肥胖患者术前至术后>6个月肌酐值的变化。次要结局包括接受MIPN与OPN的肥胖患者术前至术后3至6个月肌酐值的变化。我们还分析了在相同时间段接受部分肾切除术的非肥胖患者(BMI <30)的肌酐值。采用无条件逻辑回归估计粗比值比和多变量调整后的比值比(OR)以及95%置信区间(CI),以观察手术类型与肌酐值变化之间的关联,同时对肥胖进行分层。
共有140名患者纳入研究,其中75名肥胖,65名非肥胖。MIPN术后>6个月(n = 20),肥胖患者肌酐值降低或无变化的几率比接受OPN的患者(n = 13)高1.24倍(OR 1.24,95% CI 0.299 - 6.729;P = 0.80)。MIPN术后3至6个月(n = 27),几率比OPN术后低0.62倍(n = 17;OR 0.62,95% CI 0.140 - 2.753;P = 0.56)。在非肥胖组中,接受微创手术后3至6个月(n = 18),肌酐值降低或无变化的几率比接受开放手术的患者(n = 21)高4.86倍(OR 4.86,95% CI 1.085 - 21.809;P = 0.04)。MIPN术后超过6个月(n = 14),几率比OPN术后高4.13倍(n = 11;OR 4.13,95% CI 0.579 - 29.485;P = 0.16)。
我们观察到,接受OPN的肥胖患者术后3至6个月肾功能保留情况无统计学意义。相反,6个月后,MIPN的情况相同,表明MIPN具有长期益处。在非肥胖组中,MIPN比OPN更具优势。